KR101473966B1 - Composition for neuropsychiatric disorders comprising osmotin and expression or activity inhibitor of GABA antagonist - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing and treating neurological diseases induced by overexpression of GABA (gamma-aminobutyric acid) B receptor protein, comprising a neuroprotective agent comprising osmotin and a GABA B receptor protein activity or expression inhibitor A composition for preventing and treating diseases is provided.

Description

[0001] The present invention relates to a therapeutic agent for a neurological disease comprising an osmotin composition and a GABA B receptor protein expression or activity inhibitor,

The present invention relates to a therapeutic agent for a neurological disease, and more particularly, to a therapeutic agent for a neurological disease that contains GABA B receptor protein expression or activity inhibitor and osmotin as an active ingredient.

Gamma-aminobutyric acid (GABA) receptors are widely distributed in the central nervous system and regulate nerve activity, particularly in degenerative brain diseases and pathophysiologic disorders. For example, overexpression of the GABA B receptor has been associated with Down's syndrome (Tyler K. et al., J. Neurophysiol. , 97: 892-900, 2007), atypical seizures (Stewart LS, et al., Epilepsy Behav. , 14 (4): 577-81, 2009), Alzheimer (Palop JJ, et al., Neuron, 55: 697-711, 2007; Williams C., et al., PLoS One. ), Depression (Slattery DA et al., J. Pharmacol. Exp. Ther ., 312 (1): 290-6, 2004).

However, in the above-described neurological diseases, the molecular biological mechanism related to the GABA B receptor has not been elucidated. The present invention aims to provide a preventive and therapeutic agent for various neurological diseases induced by GABA B receptor overexpression by identifying a molecular biological mechanism associated with GABA B receptors. However, these problems are exemplary and do not limit the scope of the present invention.

According to one aspect of the present invention, there is provided a composition for preventing and treating neurological diseases, comprising osmotin and gamma-aminobutyric acid (GABA) B receptor protein activity or expression inhibitor.

The neurological disorder may be caused by GABA B receptor overexpression and may be atypical seizure, Alzheimer's, depression, or degenerative brain disease.

The GABA B receptor protein activity inhibitor may be a compound, a peptide, a peptide mimetic, an aptamer, or an antibody that binds complementarily to a GABA B receptor protein.

The compound that binds complementarily to and binds to the GABA B receptor protein is selected from the group consisting of pentylenetetrazole, phaclofen, 2-hydroxysaclofen, saclofen ), SCH-50911 (CAS # 160415-07-6, 2 - [(2S) -5,5-dimethylmorpholin- yl] acetic acid), CGP-35348 (CAS # 123690-79-9, 3-aminopropyl (diethoxymethyl) phosphinic acid), CGP-52432 (CAS # 139667- (3 - ([(3,4-Dichlorophenyl) methyl] amino] propyl) diethoxymethyl) phosphinic acid ), CGP-55845 (CAS # 149184-22-5, or (2S) -3 - ([(1S) -1- (3,4-dichlorophenyl) ethyl] amino- Methyl) phosphinic acid ((2S) -3 - ([(1S) -1- (3,4-Dichlorophenyl) ethyl] amino-2-hydroxypropyl) (phenylmethyl) phosphinic acid).

The GABA B receptor protein expression inhibitor may be an antisense nucleocleotide, a short interfering RNA, or a short hairpin RNA that complementarily binds to the mRNA of the GABA B receptor gene.

At this time, the composition according to an embodiment of the present invention may preferably contain 0.1 to 50% by weight of osmotin and GABA B receptor protein expression or activity inhibitor based on the total weight of the composition.

In addition, it may further contain at least one active ingredient which exhibits the same or similar function as the substance for inhibiting the expression or activity of GABA B receptor protein, but preferably does not exceed the content of the active ingredient.

The composition may be administered orally or parenterally at the time of clinical administration and may be administered orally or parenterally in the case of parenteral administration by intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine injection, May be administered by injection, and may be used in the form of a conventional pharmaceutical preparation.

 Each oral composition according to one embodiment of the present invention further comprises an inert ingredient, including a pharmaceutically acceptable carrier.

In practical use, the composition according to one embodiment of the present invention may be combined with a pharmaceutical carrier according to conventional pharmaceutical formulation techniques. The carrier may take a wide variety of forms depending upon the preparation desired, for example, for oral or parenteral administration (including intravenous administration).

In addition, the composition according to one embodiment of the present invention may be administered at a dose of 0.1 mg / kg to 1 g / kg, more preferably 0.1 mg / kg to 500 mg / kg. On the other hand, the dose can be appropriately adjusted according to the age, sex and condition of the patient.

According to one embodiment of the present invention as described above, it is possible to realize the effect of preventing and treating neurological diseases caused by overexpression of GABA B receptor. Of course, the scope of the present invention is not limited by these effects.

FIG. 1 is a graph (FIG. 1A) showing the effect of inhibiting the GABA B receptor expression in a composition according to an embodiment of the present invention by Western blotting and a graph (FIG. 1B) calculating the density of western blot bands.
FIG. 2 is a graph (FIG. 2A) showing the inhibitory effect of the PKA protein on the expression of the GABA B receptor in the composition according to an embodiment of the present invention by western blotting (FIG. 2A) 2B).
FIG. 3 is a graph showing the effect of suppressing the expression of p-CREB protein, which is a lower signal transduction step of the GABA B receptor of a composition according to an embodiment of the present invention, by Western blotting (FIG. 3A) and calculating the density of Western blot bands (Fig. 3B).

The terms used in this document are defined as follows.

As used herein, " antisense nucleotide " binds (hybridizes) to a complementary base sequence of DNA, immature-mRNA or mature mRNA, as defined in the Watson-click base pair, . The nature of antisense nucleotides that are specific for the target sequence makes them exceptionally multifunctional. Because antisense nucleotides are long chains of monomeric units they can be readily synthesized against the target RNA sequence. Many recent studies have demonstrated the utility of antisense nucleotides as biochemical means to study target proteins (Rothenberg et al., J. Natl. Cancer Inst. , 81: 1539-1544, 1999). The use of antisense nucleotides can be considered as a novel type of inhibitor since there has been much progress in the field of oligonucleotide chemistry and in the field of nucleotide synthesis showing improved cell adsorption, target binding affinity and nuclease resistance.

As used herein, " Peptide Minetics " is intended to inhibit the activity of GABA B receptor proteins as peptides or non-peptides that inhibit the binding domain of the GABA B receptor protein. Major residues of the non-hydrolyzable peptide analogs include the beta-turn dipeptide core (Nagai et al. Tetrahedron. Lett. , 26: 647, 1985), keto-methylene pseudopeptides (Ewenson et al. , 29: 295, 1986, and Ewenson et al ., In Peptides: Structure and Function (Pierce Chemical Co. Rockland, IL, 1985), Huffman et al. . and Biology, GR Marshall ed, ESCOM Publisher: Leiden, Netherlands, 1988), benzodiazepine (Freidinger et al in Peptides; Chemistry and Biology, GR Marshall ed, ESCOM Publisher:.. Leiden, Netherlands, 1988), β- amino alcohol (Gordon et al. Biochem. Biophys. Res. Commun., 126: 419 1985) and substituted gamma lactam rings (Garvey et al. ). ≪ / RTI >

As used herein, the term " siRNA molecule " refers to a siRNA molecule in which the sense RNA and antisense RNA form a double-stranded RNA molecule, wherein the sense RNA comprises a nucleic acid sequence identical to the target sequence of some contiguous nucleotides of the GABA B receptor mRNA . The siRNA molecule is preferably composed of a sense sequence consisting of 10 to 30 bases selected in the base sequence of GABA B receptor gene and an antisense sequence complementarily binding to the sense sequence, but not limited thereto, and GABA Any double-stranded RNA molecule having a sense sequence complementary to the base sequence of the B receptor gene can be used. Most preferably, the antisense sequence has a sequence complementary to the sense sequence.

&Quot; Antibody ", as used herein, is either manufactured through injection of an anti-GABA B receptor or commercially available. In addition, the antibody includes a polyclonal antibody, a monoclonal antibody, and a fragment capable of binding to an epitope. Polyclonal antibodies can be produced by conventional methods of injecting the GABA B receptor into the animal and obtaining blood from the animal to obtain sera containing the antibody. Such polyclonal antibodies can be purified by any method known in the art and can be made from any animal species host such as goats, rabbits, sheep, monkeys, horses, pigs, cows, dogs and the like. Monoclonal antibodies can be prepared using any technique that provides for the generation of antibody molecules through the cultivation of continuous cell lines. Such techniques include, but are not limited to, hybridoma technology, human B-cell hybridoma technology, and EBV-hybridoma technology (Kohler G et al., Nature, 256: 495-497, 1975; Coto SP et al., Proc. Natl Acad Sci., 80: 2026-2030, 1983, and Cole SP et al., &Quot; Kozbor D et al., J. Immunol. Methods, 81: 31-42, 1985; Cell. Biol., 62: 109-120, 1984). In addition, antibody fragments containing specific binding sites for the GABA B receptor can be produced. For example, F (ab ') 2 fragments can be prepared by digesting antibody molecules into pepsin, and Fab fragments can be prepared by reducing disulfide bridges of F (ab') 2 fragments, although not limited thereto. Alternatively, the Fab expression library can be miniaturized to quickly and easily identify monoclonal Fab fragments with the desired specificity (Huse WD et al., Science 254: 1275-1281, 1989). The antibody may be bound to a solid substrate to facilitate subsequent steps such as washing or separation of the complex. Solid substrates include, for example, synthetic resins, nitrocellulose, glass substrates, metal substrates, glass fibers, microspheres and micro beads. The synthetic resin includes polyester, polyvinyl chloride, polystyrene, polypropylene, PVDF, and nylon.

As used herein, " Aptamer " is a single-stranded nucleic acid (DNA, RNA or modified nucleic acid) that has a stable tertiary structure by itself and is capable of binding with high affinity and specificity to a target molecule. Since Abdomen's first exploration of the systematic Evolution of Ligands by EXponential Enrichment (Ellington, AD and Szostak, JW., Nature 346: 818-822, 1990) Numerous aptamers have been unearthed that can bind to a variety of target molecules. Aptamers are often compared with monoclonal antibodies due to their inherent high affinity (usually pM levels) and their ability to bind to target molecules with specificity, and there is a high likelihood of being an alternative antibody, particularly as a "chemical antibody".

As used herein, "pharmaceutically acceptable carrier" is a term referring to a composition, specifically a component other than the active ingredient of the pharmaceutical composition. Examples of pharmaceutically acceptable carriers include binders, disintegrants, diluents, fillers, lubricants, solubilizers or emulsifiers and salts.

Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. It should be understood, however, that the present invention is not limited to the embodiments shown in the drawings, but may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. It is provided to fully inform the category of invention to a knowledgeable person. Also, for convenience of explanation, the components may be exaggerated or reduced in size.

FIG. 1 is a graph (FIG. 1A) showing the effect of inhibiting the GABA B receptor expression in a composition according to an embodiment of the present invention by Western blotting and a graph (FIG. 1B) calculating the density of western blot bands. Overexpression of GABA B receptor protein is known to mediate a variety of neurological diseases, but the precise mechanism is unknown. Accordingly, the present inventor has tried to achieve the preventive and therapeutic effect of GABA B receptor over-expressing disease through a mechanism associated with overexpression of GABA B receptor and a composition capable of inhibiting the overexpression of GABA B receptor. (C), ethanol treatment group (E), osmotin treatment group (O), pentylenetetrazole (P), and osmotic treatment group (GABA B) receptor protein expression was assayed by Western blotting after treating the drugs according to the respective groups with the group treated with ozone + ethanol + ethanol (O + E) and the osmotin + pentylenetetrazole treated group Respectively. As a result, it was confirmed that the expression of the GABA B receptor protein significantly decreased when osmotin and pentylenetetrazol were treated together, compared with osmotin and pentylenetetrazol, respectively. In the case of osmotin, the neuronal cell death inhibitory effect is known through the present inventors' conventional studies (Korean Patent Laid-Open Publication No. 2011-0085260), but the inhibitory effect of GABA B receptor overexpression is unknown. In the case of pentylenetetrazole, it is known to be used to produce epileptic animal models characterized by reduced expression of GABA A receptor as a common epileptogenic agent (O. Carter Snead III, et al., The Journal of Neuroscience, 20 16): 6218-6224, 2000), but its effect in relation to the inhibition of GABA B receptor protein expression is unknown. That is, the above results show that a composition comprising osmotin and pentylenetetrazole can be used not only for the prevention and treatment of neurological diseases caused by overexpression of GABA B receptor protein but also for osmotin and pentylenetetrazol This is the first demonstration that there is a synergistic effect when the two compounds are treated in combination with each other.

FIG. 2 is a graph (FIG. 2A) showing the inhibitory effect of the PKA protein on the expression of the GABA B receptor in the composition according to an embodiment of the present invention by western blotting (FIG. 2A) 2B). The present inventors confirmed the expression of PKA protein, which is a sub-step of GABA B receptor, in order to elucidate the molecular mechanism of the disease caused by overexpression of GABA B receptor protein. As a result, the expression of PKA protein was observed to decrease in the order of osmotin (O), osmotin + pentylene tetrazole (O + PTZ), and pentylene tetrazole (PTZ).

FIG. 3 is a graph showing the effect of suppressing the expression of p-CREB protein, which is a lower signal transduction step of the GABA B receptor of a composition according to an embodiment of the present invention, by Western blotting (FIG. 3A) and calculating the density of Western blot bands (Fig. 3B). Following the experiment of FIG. 2, the present inventors observed the expression of p-CREB protein, which is known to be a sub-step of the GABA B receptor. However, osmotin (O), pentylenetetrazole (PTZ) and osmotene + pentylenetetrazole (O + PTZ) group.

Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. It should be understood, however, that the invention is not limited to the disclosed embodiments and examples, but may be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, It is provided to fully inform the owner of the scope of the invention.

Example 1: Animal breeding

Sparague-Dawley rats (250 g, Gyeongsang National University, Department of Neurobiology) are female and female (n = 20) Sprague-Dawley rats are housed under controlled temperature, light cycle (6: 00-20: 00) Respectively. The modified day was calculated as 0.5 day of pregnancy and pentobarbital sodium was intravenously administered at a rate of 3 mg / 100 g body weight at 17.5 days (GD 17.5 days) after pregnancy, and then the head was decapitated ).

Example 2: Primary cell culture of cerebral cortical cells

The cortical and hippocampal tissues of the GD 17.5-day-old embryo obtained from the pregnant female Sprague Dawaur rats sacrificed in Example 1 were isolated. The isolated cerebral and hippocampal tissues were treated with 0.25% trypsin EDTA for 20 minutes and physically separated from the cells by pipetting in a Hank's buffer (pH 7.4) containing no cold calcium and magnesium Followed by centrifugation. The pelleted cells were centrifuged and seeded at a density of 1x10 6 cells / ml onto a coated plate and a chamber slide using 0.02 g / l poly-lysine.

At this time, the medium was incubated with 10% FBS (fetal bovine serum), 1 mM pyruvate, 4.2 mM sodium bicarbonate, 20 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid ), DMEM (Dulbecco's modified Eagle medium) supplemented with 0.3 g / l bovine serum albumin, 50 U / ml penicillin, and 50 mg / l streptomycin. The cells were incubated at 37 ° C in a humidified condition of 5% CO 2. To prevent neuroglial cells from being cultured, the cells were cultured for 12 hours in a medium supplemented with 100 μM cytosine β-D-arabinofuranoside (Sigma, USA). After 12 hours, the medium was replaced with the above-mentioned medium. After 4 days, the cerebral cortex and hippocampal neurons were treated with 100 mM ethanol (E, negative control), osmotin 0.08 μM (O, positive control), 20 mM pentylenetetrazole (PTZ, Treatment group was divided into 0.08 μM osmotone + 20 mM pentylenetetrazol treated group (O + PTZ, experimental group 2), 0.08 μM osmotin + 100 mM ethanol treated group (O + E, (See Table 1). All drugs were commonly treated for 24 hours in cell culture.

Experimental group according to drug treatment Treatment Drug and Throughput Control group Untreated group (C) Negative control group Treated with 100 mM ethanol (E) Positive control group 0.0 > M < / RTI > treated group (O) Experiment 1 Pentylenetetrazole 20 mM treatment group (PTZ) Experiment 2 Osmotin 0.08 M + pentylenetetrazole 20 mM treatment group (O + PTZ) Comparison group 1 Osmotin 0.08 M + ethanol 100 mM treated group (O + E)

Example 3: Purification of osmotin

Osmotin contained in the composition according to one embodiment of the present invention was isolated from salt-adapted tobacco cultured cells (Nicotiana tabacum L. var. Wisconsin 38) at a purity of 99% or more (Yun et al., Proc Natl Acad Sci USA , 94 (13): 7082-7, 1997; Yun DJ et al. , Mol. Cell. , 1 (6): 807-17, 1998).

Experimental Example 1: Inhibitory effect of GABAB1R protein expression

In order to demonstrate the therapeutic and prophylactic effects of the above-mentioned composition containing osmotin and pentylenetetrazol on the abnormal epilepsy and cognitive-related disorders caused by overexpression of GABAB receptors, in Examples 1 and 2, After culturing the cerebral and hippocampal cells of the obtained rats, the drugs listed in Table 1 were treated for 24 hours. The expression of the GABA1B receptor was then confirmed by Western blotting.

First, the cerebral cortex and hippocampal cells cultured in Example 2 were homogenized using a cell lysis buffer (Cell signaling # 9803) containing 100 mM of protease inhibitor PMSF. Protein samples were placed on ice for 20 minutes and sonicated for 4 minutes (15 seconds on / 10 seconds off). Thereafter, centrifugation was carried out at 12,000 g for 10 minutes, which was repeated twice, and only supernatant containing protein was obtained.

Protein concentration was measured using a Bio-Rad (Hercules, CA) protein assay and was measured by spectrophotometry at 595 nm after loading at a rate of 30 μg protein / lane.

Then, the soluble fraction (30 μg) was dissolved in 12% SDS-polyacrylamide gel [30% Acrylamide, 1% Bis, 1 M Tris, 10% SDS, 10% APS and TEMED ], Where it was repeatedly separated in two gels. One gel separated from the protein was stained with Comassie Blue, and the remaining gel was transferred to a nitrocellulose membrane through transfer buffer [48 mM Tris, 39 mM glycine, 20% MeOH and 0.037% SDS] under the condition of 90V constant for 1 hour. The nitrocellulose membrane was then blocked with a blocking solution (Tris-buffered saline (TBS) buffer containing 0.1% (v / v) Tween 20 and 6% (w / v) skimmed milk to prevent nonspecific binding of the antibody ]. The blocked membranes were reacted with rabbit-polyclonal IgG GABAB1 or rabbit-derived anti-rabbit GABAB1R antibody (1: 1000, Abcam Limited, UK) at 4 ° C for 24 hours to induce an immune response. After removing the antibody, goat anti-mouse HRP (horseradish peroxidase) -based goat anti-rabbit IgG HRP (1: 10000, Bio-Rad) and the nitrocellulose membrane were reacted at room temperature for 2 hours. Proteins were then detected by chemiluminescence using ECL detection reagents (Amersham Pharmacia Biotech, Western blotting detection reagents) and ECL detection was performed according to the protocol described in Amersham.

As a result, as shown in FIG. 1A, it was confirmed that the expression of GABAB1R protein significantly decreased the expression of the protein when the two drugs were treated together, as compared with when a single component of osmotin and pentylenetetrazol was treated .

Next, the present inventors analyzed the density of the band observed as a result of Western blotting using a computer-based Sigma gel system (SPSS Inc. Chicago, USA) using a density meter, ), Respectively. One-way ANOVA analysis according to the Tukey-Kramer multiple comparison test was performed to analyze the significance between the experimental groups. In all experiments, P <0.05 was considered statistically significant.

As a result, the expression of GABA1BR protein observed when a single component of osmotin and pentylenetetrazole was treated was decreased compared with that of the control (C), but the degree of expression between the experimental groups was similar, and osmotin and pentylenetetrazole The combined treatment group showed a 7 ~ 8 fold lower expression level than the single drug treated group.

These results suggest that a composition comprising osmotin and pentylenetetrazol according to one embodiment of the present invention in epilepsy, such as atypical seizure, which may be caused by overexpression of GABABR, .

Experimental Example 2: Inhibitory effect of GABAB1R sub-step protein expression

In order to confirm that a composition comprising osmotin and pentylenetetrazole according to an embodiment of the present invention is useful for the treatment and prevention of atypical seizure-induced seizures induced by overexpression of GABA receptor, the inhibition of GABAB1R protein expression, And the expression of PKA protein and pCREB protein was inhibited.

Cells were cultured under the same conditions as in Experimental Example 1, treated with drugs, and then the level of expression of PKA protein was confirmed through Western blotting. Western blotting was performed in the same manner as in Experimental Example 1 except that p-CREB and PKA-α antibody (1: 1000, Santa Cruz, Cell signaling) were used as antibodies.

As a result, the expression of PKA and p-CREB protein was not significantly suppressed compared with that of a single drug, unlike the effect of suppressing the expression of GABA B receptor protein in the group treated with osmotin and pentylenetetrazole. In the case of PKA, expression decreased in the order of osmotin (O), osmotin + pentylenetetrazole (O + PTZ), and pentylenetetrazole (PTZ). In the case of p-CREB, There was no significant difference between the two groups. These results indicate that further research is needed on the molecular biological mechanisms mediated by the overexpression of GABA B receptors by compositions comprising osmotin and pentylenetetrazole according to one embodiment of the present invention do.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. Accordingly, the true scope of the present invention should be determined by the technical idea of the appended claims.

Claims (6)

Osmotin and i) an antibody that specifically binds to a GABA (gamma-aminobutyric acid) B1 receptor protein, ii) an aptamer that specifically binds to GABA B1 receptor, and iii) pentylenetetrazole. , Phaclofen, 2-hydroxysaclofen, saclofen, SCH-50911 (CAS # 160415-07-6), CGP-35348 (CAS # 123690-79 -9), CGP-52432 (CAS # 139667-74-6), and CGP-55845 (CAS # 149184-22-5) A short interfering RNA, and a short hairpin RNA complementarily binding to GABA B1 receptor activity inhibitor or mRNA of the GABA B1 receptor gene selected from the group consisting of: Atypical Insomnia, Alzheimer &amp; Depression, &lt; RTI ID = 0.0 &gt; The composition for treatment and prevention of neurological diseases selected from the group consisting of. The method according to claim 1,
Wherein said neurological disease is caused by overexpression of a GABA B receptor. delete delete delete delete

Images